Showing results (201-210 of 234) with videos related to
Sort By:
Pageof 24
Gastroenterology|January 18, 2012
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis CTom W Chu, Rohit Kulkarni, Edward J Gane, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2021
Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric NeoplasmsHimalee S Sabnis, David S Shulman, Benjamin Mizukawa, et al.Antimicrobial Agents and Chemotherapy|December 4, 2013
Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null respondersEdward J Gane, Régine Rouzier, Alicja Wiercinska-Drapalo, et al.Journal of Hepatology|October 18, 2015
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeksJordan J Feld, Christophe Moreno, Roger Trinh, et al.Liver International : Official Journal of the International Association for the Study of the Liver|February 13, 2014
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4Gregory Everson, Curtis Cooper, Christophe Hézode, et al.Liver International : Official Journal of the International Association for the Study of the Liver|May 13, 2014
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR studyEdward J Gane, Paul J Pockros, Stefan Zeuzem, et al.Journal of Viral Hepatitis|November 20, 2018
Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infectionJacinta A Holmes, Charles Carlton-Smith, Arthur Y Kim, et al.Journal of the National Cancer Institute|June 26, 2024
Poverty, race, ethnicity, and survival in pediatric nonmetastatic osteosarcoma: a Children's Oncology Group reportLenka Ilcisin, Ruxu Han, Mark Krailo, et al.Lancet (London, England)|October 19, 2010
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trialEdward J Gane, Stuart K Roberts, Catherine A M Stedman, et al.JCO Precision Oncology|May 14, 2026
Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN StudyHolly J Roberts, Hannah Comeau, Kelly Klega, et al.Pageof 24